PMID- 28219220
OWN - NLM
STAT- MEDLINE
DCOM- 20180522
LR  - 20200717
IS  - 0253-2727 (Print)
IS  - 2707-9740 (Electronic)
IS  - 0253-2727 (Linking)
VI  - 38
IP  - 1
DP  - 2017 Jan 14
TI  - [Clinical significance of expressions of EVI1 and BRE genes in 47 acute leukemia 
      patients with MLL rearrangement].
PG  - 22-27
LID - 10.3760/cma.j.issn.0253-2727.2017.01.005 [doi]
AB  - Objective: To investigate the overexpression frequencies of BRE and EVI1, the 
      correlation between BRE and EVI1 expressions and their possible clinical 
      implications in 11q23/MLL rearrangement acute leukemia. Methods: Cytogenetic 
      examination of bone marrow cells was performed by short-term culture method. 
      R-banding technique was used for karyotype analysis. 47 patients were detected by 
      interphase fluorescence in situ hybridization (FISH) with dual-color break apart 
      MLL probe. The expressions of EVI1 and BRE genes were detected by real time 
      quantitative reverse transcription polymerase chain reaction (RQ-PCR) . The 
      correlation and prognostic significance were statistically tested. Results: 
      11q23/MLL rearrangements were confirmed by karyotyping and FISH, respectively in 
      47 patients. According to immunophenotypic analyses of 37 patients, 5 patients 
      showed positive for CD19, CD79a or CD10, 1 for CD7; the others for CD33, CD13, 
      CD14 and CD15, and 16 of them for CD34. Of the 47 patients, 18 patients showed 
      EVI1 overexpression and most of them presented with t (6;11) and M(4)/M(5). The 
      EVI1 expression was high in t (6;11) or t (9;11) subgroup comparable with levels 
      observed in normal subgroup (P=0.038, 0.022, respectively) . 15 patients showed 
      high BRE expression, and most of them presented with t (9;11) and M(4)/M(5). High 
      BRE expression was found in t (4;11) , t (6;11) , t (9;11) and t (11;19) 
      subgroups, respectively by comparing with normal subgroup. The BRE expression was 
      higher in t (4;11) (P=0.004) or t (9;11) (P=0.012) subgroup than in t (6;11) 
      subgroup. Patients with EVI1 overexpression had a short survival compared with 
      those with low EVI1 expression (P=0.049) and it also did in t (9;11) subgroup 
      (P=0.024) . Patients with t (9;11) and high BRE expression had a long survival 
      compared with those with t (9;11) and low BRE expression (P=0.024) . Conclusion: 
      The EVI1 overexpression was significantly frequent in acute leukemia patients 
      with 11q23/MLL rearranged, especially within t (6;11) subgroup and M(4)/M(5), 
      which was associated with an inferior outcome. High BRE expression was observed 
      frequently in 11q23/MLL-rearranged acute leukemia especially within t (9;11) 
      subgroup and M(5).
FAU - Gong, Y L
AU  - Gong YL
AD  - Department of Hematology, The First Affiliated Hospital of Soochow University, 
      Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Homeostasis, 
      Suzhou 215006, China.
FAU - Zhang, J R
AU  - Zhang JR
FAU - Zhang, J
AU  - Zhang J
FAU - Bai, S X
AU  - Bai SX
FAU - Cen, J N
AU  - Cen JN
FAU - Shen, H J
AU  - Shen HJ
FAU - Chou, H Y
AU  - Chou HY
FAU - Chen, S N
AU  - Chen SN
FAU - Pan, J L
AU  - Pan JL
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Xue Ye Xue Za Zhi
JT  - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
JID - 8212398
RN  - 0 (KMT2A protein, human)
RN  - 149025-06-9 (Myeloid-Lymphoid Leukemia Protein)
RN  - EC 2.1.1.43 (Histone-Lysine N-Methyltransferase)
SB  - IM
MH  - Acute Disease
MH  - Bone Marrow Cells
MH  - Chromosome Banding
MH  - *Chromosomes, Human, Pair 11
MH  - Gene Rearrangement
MH  - Histone-Lysine N-Methyltransferase
MH  - Humans
MH  - Immunophenotyping
MH  - In Situ Hybridization, Fluorescence
MH  - Interphase
MH  - Karyotyping
MH  - *Leukemia, Myeloid, Acute
MH  - Myeloid-Lymphoid Leukemia Protein
MH  - Prognosis
MH  - Real-Time Polymerase Chain Reaction
PMC - PMC7348406
OTO - NOTNLM
OT  - Gene rearrangement, MLL
OT  - Gene, BRE
OT  - Gene, EVI1
OT  - In situ hybridization, fluorescence
OT  - Leukemia, acute
EDAT- 2017/02/22 06:00
MHDA- 2018/05/23 06:00
PMCR- 2017/01/01
CRDT- 2017/02/22 06:00
PHST- 2017/02/22 06:00 [entrez]
PHST- 2017/02/22 06:00 [pubmed]
PHST- 2018/05/23 06:00 [medline]
PHST- 2017/01/01 00:00 [pmc-release]
AID - cjh-38-01-022 [pii]
AID - 10.3760/cma.j.issn.0253-2727.2017.01.005 [doi]
PST - ppublish
SO  - Zhonghua Xue Ye Xue Za Zhi. 2017 Jan 14;38(1):22-27. doi: 
      10.3760/cma.j.issn.0253-2727.2017.01.005.